Fixation of OsseoTi™ Porous Structure Versus PPS (Porous Plasma Spray) Coating on the G7™ Acetabular Component for Primary Total Hip Arthroplasty
Key facts
- Who runs it
- Hvidovre University Hospital
- Where
- Denmark and Sweden2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 98 people, planned
- Started
- Dec 2014
- Expected to end
- Apr 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- THA with G7 PPS coted acetabular component
- THA with G7 OsseoTi coted acetabular component
- Record updated
- 9 February 2021
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- • Participants with primary hip osteoarthritis set to receive a primary unilateral uncemented total hip arthroplasty; Participants must be 18-75 years of age; Participants must be able to speak and understand Danish (or depending on country where patient is enrolled); Participants must be able to give informed consent and be cognitively intact; Participants must be expected to be able to complete all postoperative controls; Participants must not have severe comorbidities, ASA-score ≤ 3
Who cannot take part
- Previous fracture of the hip
- Previous infection of the hip
- Severe bony deformity warranting the use of non-standard implants
- Terminal illness
- Participants that develop deep infection in the follow-up period are excluded from the project
- Rheumatoid arthritis
- Osteonecrosis of the hip
- Metastasis in the periarticular bone or proximal femur
- Female patients that are pregnant or planning pregnancy during follow-up period
- If bone stock or femoral canal type, assessed on preoperative x-ray, warrants the use of cemented fixation
- Documented osteoporosis with patient in active medical treatment
- Comorbidity with altered pain perception (e.g. DM with neuropathy)
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this project is to investigate, using RSA, acetabular implant migration of the OsseoTi™ G7 acetabular cup in comparison to conventional PPS coated G7 acetabular cup, and compare liner wear of thinnest available E1™ liner, allowing for the largest possible femoral head (36mm-44mm) to E1™ liner holding a 32mm femoral head in the G7 acetabular system with endpoint assessment being performed at the 2 year follow-up.
The 4 groups in the trial
- OsseoTi™ G7 largeExisting treatment, for comparison
OsseoTi™ G7 acetabular cup and an E1™ liner holding largest possible femoral head (36mm-44mm)
Treatment: THA with G7 PPS coted acetabular component and THA with G7 OsseoTi coted acetabular component
- OsseoTi™ G7 32Existing treatment, for comparison
OsseoTi™ G7 acetabular cup and an E1™ insert holding a 32mm femoral head
Treatment: THA with G7 PPS coted acetabular component and THA with G7 OsseoTi coted acetabular component
- conventional PPS coated G7 largeExisting treatment, for comparison
conventional PPS coated G7 acetabular cup and an E1™ insert holding largest possible femoral head (36mm-44mm)
Treatment: THA with G7 PPS coted acetabular component and THA with G7 OsseoTi coted acetabular component
- conventional PPS coated G7 32Existing treatment, for comparison
conventional PPS coated G7 acetabular cup and an E1™ insert holding a 32mm femoral head
Treatment: THA with G7 PPS coted acetabular component and THA with G7 OsseoTi coted acetabular component
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Fixation of OsseoTi™ Porous Structure Versus PPS (Porous Plasma Spray) Coating on the G7™ Acetabular Component for Primary Total Hip Arthroplasty: A Single-Blinded Randomized Controlled Trial Evaluating Implant Migration, Acetabular Liner Wear, and Patient Reported Outcome
- Record updated
- 9 February 2021